Bacterial glutamine synthetases as selectable markers in mammalian cells

By using glutamine synthase and its mutants from Provendis larvae as selection markers in mammalian cells, the problems of insufficient activity and poor selection stringency in the prior art were solved, and high yields were achieved and stable cell line development improves antibody titer and cell culture performance.

CN118900915APending Publication Date: 2024-11-05BOEHRINGER INGELHEIM INT GMBH
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202380028185.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-23
Filing Date
2023-03-22
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Prior art When using bacterial glutamine synthase as a selection marker in mammalian cells, there are problems of insufficient activity and poor selection stringency, which affects the stability and productivity of the cell line.

Method used

The glutamine synthase and its mutants from Provendis larvae as selection markers were used to achieve stable expression and selection in culture medium without glutamine by binding to the expression vector of mammalian cells. Enhance selection stringency and productivity.

Benefits of technology

It significantly improves the selection stringency of cell lines and antibody titers, extends the stability of productivity, reduces the probability of recombinant events, and improves cell culture performance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005046350230000191
    Figure BDA0005046350230000191
  • Figure BDA0005046350230000261
    Figure BDA0005046350230000261
  • Figure BDA0005046350230000271
    Figure BDA0005046350230000271
Patent Text Reader

Abstract

The present invention relates to mammalian expression vectors comprising a polynucleotide encoding a bacterial glutamine synthetase as a selection marker, and to nucleic acids and mammalian host cells encoding the bacterial glutamine synthetase. In particular, the bacterial glutamine synthetase is derived from bacteria of the family Enterobacter and Morgan, preferably, the bacterial glutamine synthetase is a glutamine synthetase of the genus Providencia, optionally further comprising a mutation in position E130 and / or F226 and / or R345A. The invention further relates to methods for preparing mammalian cells that stably express a protein of interest and / or non-coding RNA, and methods for producing proteins in mammalian cells using said bacterial glutamine synthetases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a mammalian expression vector comprising a polynucleotide encoding a bacterial glutamine synthetase as a selection marker, the polynucleotide having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 1, and to nucleic acids encoding the bacterial glutamine synthetase and mammalian host cells. In particular, the bacterial glutamine synthetase is derived from bacteria of the Enterobacterales and Morganellaceae, preferably, the bacterial glutamine synthetase is a Providencia species glutamine synthetase, optionally further comprising mutations in positions E130 and / or F226 and / or R345. The present invention further relates to a method for preparing mammalian cells stably expressing a protein and / or non-coding RNA of interest, and a method for using the bacterial glutamine synthetase for producing proteins in mammalian cells. Background Art

[0002] Chinese hamster ovary (CHO) cells are one of the most commonly used mammalian cell lines for the production of therapeutic proteins such as antibodies. An important aspect is the generation of high-yield and stable cell lines that express the protein of interest in a short period of time and with high product titer with suitable product quality. In order to produce stable and high-yield cell lines, a selection phase is required to generate a stable heterogeneous cell pool consisting of different clones, which needs to be separated and screened before the final production cell line can be stored in a cell bank. Metabolic selection systems such as dihydrofolate reductase (DHFR) and glutamine synthetase (GS) selection systems are generally used to improve this process, and more effectively generate stable cell lines.

[0003] In cell lines lacking the DHFR gene, such as CHO-DG44 cells, selection is performed in the absence of hypoxanthine and thymidine in the culture medium. In addition, an amplification step by adding increasing concentrations of methotrexate (MTX) can be used. The GS selection system is advantageous because it requires fewer gene copies for survival, and therefore selection for high-yield cell pools is faster.

[0004] Glutamine synthetase (EC 6.3.1.2, also known as γ-glutamyl: ammonia ligase) catalyzes the condensation of ammonia and glutamate of ATP dependence to form glutamine. Glutamine synthetase is classified into three subgroups: GSI, GSII and GSIII. CHO GS is a class II enzyme, which is predominantly expressed by eukaryotic organisms, while bacterial GS proteins are usually members of the GSI class. Although GSI and GSII catalyze the same reaction, they do not show sequence similarity or show very little sequence similarity except for the residues that constitute the part of the active site, and are generally quite different. For example, bacterial type I GS is a 12-subunit complex (Eisenberg et al. (2000), Biochim.Biophys.Acta 1477, 122-145), and GSII has been reported to form two or three five-membered ring stacks (Krajewski et al. (2008), J.Mol.Biol.375, 217-228). In addition, bacterial GS can have very little sequence similarity with each other, for example, Bacillus coagulans (CN12625930 A) or Mycobacterium tuberculosis (WO 2006 / 000045) or Cornybacterium glutamicum (CN 1884501 A) and Providencia vermicola GS have an amino acid identity as low as about 50% or less (Zuo et al., Scientific Reports, 2018, 8(1): 1-8 and supplementary materials).

[0005] GS is a ubiquitous enzyme essential for nitrogen metabolism. Therefore, GS has been used as a selection marker introduced via a mammalian expression construct. In cell lines that do not express sufficient levels of endogenous GS, removing glutamine from the cell culture medium increases the selection pressure on the cells. In cell lines with insufficient endogenous GS levels, such as mouse myeloma cell lines, cultivation in the absence of glutamine or lack of glutamine supplementation provides sufficient selection pressure to separate stable recombinant cell lines. In cell lines with sufficient endogenous GS, such as CHO cells, the addition of the GS inhibitor methionine sulfoximine (MSX) or the generation of GS knockout cells (GS- / - or GS- / +) is required to allow sufficient selection pressure in the absence of glutamine to separate productive cell lines. The selection stringency in CHO GS knockout cells is greatly improved, and it has been further reported that the expression of the GS gene transfected under the control of a weak promoter improves the selection stringency, with or without the use of MSX. In addition to selection stringency and productivity, the stability of protein production of high-yield clones has been shown to be a key attribute.

[0006] In addition, the transfected glutamine synthetase selection marker has a significant impact on the phenotypic stability and productivity of the selection process and CHO-based cell lines. For example, the use of attenuated variants of CHO glutamine synthetase further showed improved stability, selection behavior and productivity (Lin et al. (2019), mAbs, 11: 5, 965-976; WO 2018 / 093331, US20190352631, WO 2017 / 197098). Most of the described attenuated variants have mutations in conserved substrate binding residues. For example, two attenuated GS mutants containing R324C and R341C mutations were first identified in two unrelated infants with congenital GS deficiency (Lin et al. (2019), mAbs, 11: 5, 965-976). The residues reported to be involved in glutamate binding are E134, E136, E196, E203, N248, G249, H253, R299, R319, E338 and R340; the residues reported to be involved in ATP binding are W130, A191, G192, P208, N255, S257, R262, R324 and Y336; and the residues involved in amine binding are D63, S66, D162 and E305 (amino acid numbering refers to human GS) (Krajewski et al. (2008), J. Mol. Biol. 375, 217-228 and WO 2018 / 093331).

[0007] Although attenuated GS variants with mutations in the active site show increased selection stringency, the duration of the selection process and overall cell growth properties may be compromised, negatively affecting bioprocess performance. Attenuation of selection markers is a delicate balance between selection stringency, integrated copy number, and appropriate cell culture properties (e.g., growth behavior) to support the manufacture of recombinant proteins. Therefore, there is a need to develop novel attenuated GS variants to improve mammalian expression vectors in cell line development.

[0008] Although bacterial GS or its peptides from various species have been expressed in eukaryotic cells such as yeast for purification, as immunogens or other reasons (see, e.g., WO 2018 / 144807, WO 2006 / 000045 A1), and yeast or plant GS were shown to be active in E. coli, but vice versa (WO 2004 / 003175 A2 and EP 0 240 792 A1), bacterial GS (GSI) is assumed to be inactive in mammalian cells. More importantly, to our knowledge, bacterial GS has not been tested in mammalian cells or used as a selection marker before. Summary of the invention

[0009] The present invention demonstrates that certain bacterial glutamine synthetase genes unrelated to mammalian glutamine synthetase genes can be used to generate high-yield and stable pools of mammalian host cells expressing therapeutic proteins, particularly therapeutic antibodies, showing more stringent selection behavior due to reduced activity compared to wild-type glutamine synthetase, and beneficial cell culture performance in mammalian cells such as CHO cells. This is the first time that prokaryotic glutamine synthetase variants have been used to generate stable and high-yield mammalian cell pools for cell line development. Further, point mutations of Providencia larvae glutamine synthetase were identified that showed extended selection stringency and improved antibody titers compared to wild-type Providencia larvae glutamine synthetase. Another advantage of bacterial GS selection markers is that, due to the low sequence similarity to mammalian (e.g., CHO) GS, the probability of recombination events that restore endogenous GS genes and thus cause cells that do not produce the gene of interest to survive is dramatically reduced.

[0010] In a first aspect, the present invention relates to a mammalian expression vector comprising a polynucleotide encoding a bacterial glutamine synthetase as a selection marker, wherein the bacterial glutamine synthetase has at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1. In certain embodiments, the bacterial glutamine synthetase is derived from bacteria of the order Enterobacteriales and the family Morganellaceae. In certain embodiments, the bacterial glutamine synthetase is derived from a species of the genus Providencia and / or comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1. In certain embodiments, the bacterial glutamine synthetase is derived from a species of the genus Photorhabdus and / or comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 14. In a preferred embodiment, the bacterial glutamine synthetase is a Providencia larvae glutamine synthetase or a luminescent Photorhabdus glutamine synthetase.

[0011] The mammalian expression vector may further encode a bacterial glutamine synthetase comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, and comprising a mutation selected from the group consisting of E130X, F226Y, R345A, and combinations thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, more preferably selected from the group consisting of Y, W, F, A, G, V, L, M, and I. In certain embodiments, the amino acid sequence has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 14, and a mutation selected from the group consisting of E130X, F226Y, R345A, and combinations thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, more preferably selected from the group consisting of Y, W, F, A, G, V, L, M, and I.

[0012] In certain embodiments, the mammalian expression vector further comprises at least one polynucleotide encoding a protein and / or non-coding RNA of interest, preferably an expression cassette comprising at least one polynucleotide encoding a protein and / or non-coding RNA of interest. The protein of interest is preferably a therapeutic protein, more preferably selected from cytokines, hormones, fusion proteins, antibodies, antibody-derived molecules, and antibody mimetics.

[0013] The present invention further provides a nucleic acid sequence comprising a polynucleotide encoding a bacterial glutamine synthetase operably linked to a mammalian promoter, optionally further comprising at least one polynucleotide encoding a protein of interest and / or a non-coding RNA. In certain embodiments, the bacterial glutamine synthetase comprises an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, and comprising a mutation selected from E130X, F226Y, R345A, and combinations thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, more preferably selected from Y, W, F, A, G, V, L, M, and I.

[0014] In yet another aspect, the present invention provides a bacterial glutamine synthetase from Providencia larvae, comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, and comprising a mutation selected from E130X, F226Y, R345A and combinations thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, more preferably selected from Y, W, F, A, G, V, L, M and I.

[0015] In another aspect, the present invention provides a mammalian host cell comprising an expression vector according to the present invention, a nucleic acid sequence according to the present invention, or a nucleic acid sequence encoding a bacterial glutamine synthetase according to the present invention, preferably wherein the mammalian host cell is (a) a rodent cell, more preferably a CHO cell and / or (b) a GS gene knockout cell. Preferably, the polynucleotide encoding the bacterial glutamine synthetase is co-integrated into the host cell genome with at least one polynucleotide encoding a protein and / or non-coding RNA of interest.

[0016] In another aspect, the present invention provides a method for preparing a cell that stably expresses a protein and / or non-coding RNA of interest, comprising (a) introducing an expression vector according to the present invention or a nucleic acid according to the present invention into a mammalian host cell, preferably a CHO cell, wherein the expression vector or nucleic acid comprises a polynucleotide encoding a bacterial glutamine synthetase and at least one polynucleotide encoding a protein and / or non-coding RNA of interest; and (b) culturing the mammalian host cell under conditions that select for bacterial glutamine synthetase in a medium that does not contain glutamine, wherein at least one polynucleotide encoding a protein and / or non-coding RNA of interest is co-integrated with a polynucleotide encoding a bacterial glutamine synthetase into the host cell genome. In certain embodiments, the method further comprises (c) a step of isolating a single clone for clonal amplification to prepare a monoclonal cell line. In this case, the method is a method for preparing a monoclonal cell line that stably expresses a protein and / or non-coding RNA of interest.

[0017] The present invention further provides a method for producing a protein of interest, comprising (a) introducing a mammalian expression vector according to the present invention or a nucleic acid according to the present invention into a mammalian host cell, preferably a CHO cell, wherein the expression vector comprises a polynucleotide encoding a bacterial glutamine synthetase operably linked to a mammalian promoter and at least one polynucleotide encoding a protein of interest; (b) culturing the mammalian host cell in a glutamine-free medium under conditions that select for bacterial glutamine synthetase, wherein the at least one polynucleotide encoding the protein of interest is co-integrated with the polynucleotide encoding the bacterial glutamine synthetase into the host cell genome; (c) optionally isolating individual clones for clonal amplification to prepare monoclonal cell lines; (d) culturing the mammalian host cell under conditions that produce the protein of interest; and (e) harvesting and optionally purifying the protein of interest.

[0018] In another aspect, a method for producing a protein of interest is provided, comprising (a) providing a mammalian host cell of the present invention, comprising a polynucleotide encoding a bacterial glutamine synthetase operably linked to a mammalian promoter and at least one polynucleotide encoding a protein of interest; (b) culturing the mammalian host cell under conditions for producing the protein of interest; and (c) harvesting and optionally purifying the protein of interest. Preferably, the mammalian host cell is a rodent cell, more preferably a CHO cell.

[0019] In a further aspect, the present invention relates to a kit comprising an expression vector according to the present invention and a cell culture medium without glutamine.

[0020] In another aspect, the present invention provides the use of bacterial glutamine synthetase as a selection marker in mammalian cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 : Pool of CHO-K1-GS cells expressing mAb1 and wild-type CHO GS as a selection marker. Pool of CHO-K1-GS cells (n=5) stably transfected with a mammalian expression vector to express mAb1 and CHO wild-type GS as a metabolic selection marker were cultured in medium without L-glutamine. The titer of mAb1 [mg / L] was determined on the indicated days after transfection.

[0022] Figure 2 : Viability and viable cell density (VCD) of CHO-K1-GS expressing mAbl and wild-type CHO GS or Providencia larvae GS as selection marker. Pools of CHO-K1-GS cells stably transfected with vectors encoding mAbl and a transcription cassette for the glutamine synthetase selection marker from Cricetulus griseus or Providencia larvae were cultured in medium without L-glutamine. A) Viability [%] during selection and B) viable cell density were determined at the indicated days after transfection.

[0023] Figure 3 : Productivity after selection of CHO-K1-GS expressing mAbl and wild-type CHO GS or P. larvae GS as selection marker and shake flask production runs. Pools of CHO-K1-GS cells stably transfected with a vector encoding mAbl and a transcription cassette for the glutamine synthetase selection marker from Chinese hamster (CHO WT GS) or P. larvae were cultured in medium without L-glutamine. Productivity as titer [mg / L] (A) was determined at the indicated days after transfection after selection using CHOWT GS or P. larvae GS as selection marker and (B) was determined in shake flask production runs only for P. larvae GS at the indicated days after transfection, since CHO WT GS cells lose their productivity after about 20 days.

[0024] Figure 4 : Viability and productivity after transfection of CHO-K1-GS expressing mAbl and GS from Providencia larvae, Photorhabdus luminescens and Budvicia aquatica as selection markers. Pools of CHO-K1-GS cells stably transfected with vectors encoding mAbl and transcription cassettes for glutamine synthetase selection markers from Providencia larvae (filled circles), Photorhabdus luminescens (filled squares) and Budvicia aquatica (filled triangles) were cultured in medium without L-glutamine. A) Viability [%] during selection was determined at the indicated days after transfection. (B) Productivity as titer [mg / L] was determined after selection at the indicated days after transfection.

[0025] Figure 5 : Shake flask production runs of CHO-K1-GS expressing mAb1 and wild-type P. larvae GS or P. larvae GS E130F / E130G mutants as selection markers. Pools of CHO-K1-GS cells stably transfected with a transcription cassette to express mAb1 and P. larvae GS or P. larvae GS with E130F or E130G mutations as selection markers were cultured in medium without L-glutamine. The titers [mg / L] of mAb1 were determined at the indicated days after transfection.

[0026] Figure 6 : Productivity and viable cell density (VCD) in shake flask production runs of CHO-K1-GS expressing mAbl and P. larvae wild-type GS, CHO wild-type GS, or P. larvae F226Y variant as selection markers. After stable pool generation and single cell sedimentation, selected high-producing clones were subjected to head-to-head shake flask experiments with CHO WT (14-day production run). (A) Productivity as mAbl titer [mg / L] using P. larvae wild-type GS, P. larvae GS F226Y, or CHO GS WT as selection markers, and (B) viable cell density [1x10 6 cells / ml] were determined at the end of the production run.

[0027] Figure 7 : Viability and productivity after transfection of CHO-K1-GS expressing mAbl and P. larvae wild-type GS or P. larvae R345A or R360A variants as selection markers. Pools of CHO-K1-GS cells stably transfected with vectors encoding mAbl and a transcription cassette for the glutamine synthetase selection marker from P. larvae WT GS (filled circles) and P. larvae R345A (filled squares) or R360A variants (filled triangles) were cultured in medium without L-glutamine. A) Viability [%] during selection was determined for P. larvae wild-type GS and the two variants at the indicated days after transfection. (B) Productivity as titer [mg / L] was determined at the indicated days after selection, normalized to >70% viability for P. larvae wild-type GS and P. larvae R345A variant, as the P. larvae R360A variant was not recovered during selection.

[0028] Figure 8 : Sequence of Providencia larvae glutamine synthetase (SEQ ID NO: 1)

[0029] Fig. 9 : Sequence of wild-type Chinese hamster glutamine synthetase (SEQ ID NO: 2)

[0030] Fig.10 : Sequence of Photorhabditis luminescens glutamine synthetase (SEQ ID NO: 14) DETAILED DESCRIPTION

[0031] The term "comprises" or "comprising" means "including but not limited to". The term is intended to be open-ended to specify the presence of any of the features, elements, integers, steps or components, but does not exclude the presence or addition of one or more other features, elements, integers, steps, components or groups thereof. Therefore, the term "comprising" includes the stricter terms "consisting of" and "consisting essentially of". With respect to sequences, the terms "amino acid sequence having" and "comprising amino acids" are used interchangeably and include embodiments of "consisting of an amino acid sequence of". Similarly, the term "encoding" or "encodes" is intended to be open-ended and allows the presence or addition of one or more other features, elements or components. In addition, the singular and plural forms are not used in a restrictive manner. As used herein, the singular forms "a", "a kind of" and "the / said" specify both the singular and the plural, unless explicitly stated to specify only the singular.

[0032] The terms "protein" and "amino acid sequence" or "polypeptide" are used interchangeably and refer to polymers of amino acids of any length. These terms also include proteins that are post-translationally modified by reactions including, but not limited to, glycosylation, acetylation, phosphorylation, glycation, or protein processing. Modifications and changes can be made in the structure of a polypeptide, such as fusions to other proteins, amino acid sequence substitutions, deletions, or insertions, while the molecule maintains its biological functional activity. For example, certain amino acid sequence substitutions can be made in a polypeptide or its underlying nucleic acid coding sequence, and a protein with the same properties can be obtained.

[0033] The term "nucleic acid sequence" is used interchangeably with "polynucleotide" and refers to DNA or RNA of any length. In the context of expression vectors, particularly plasmids, and integration into the genome of host cells, those skilled in the art will understand that it refers to a DNA sequence or molecule.

[0034] As used herein, the term "eukaryotic cell" refers to a cell having a nucleus within a nuclear envelope, and includes animal cells, human cells, plant cells, and yeast cells. Eukaryotic cells particularly encompass mammalian cells, such as cells derived from Chinese hamster ovary (CHO) cells or HEK293 cells. As used herein, mammalian cells refer to all cells or cell lines of mammalian origin, such as human or rodent cells. Cells as mentioned herein are cells maintained in culture, and are not related to primary cells, but are cell lines or cell line-derived cells, i.e. immortalized cells.

[0035] As used herein, the term "about" refers to a 10% variation of the specified value, for example, about 50% carries a variation of 45 to 55%.

[0036] As used herein, the term "selection stringency" refers to the duration of time after transfection for a cell culture to reach more than 70% viability and a doubling time of 48 hours or less. The longer the time period, the more stringent the selection behavior. Typically, attenuated glutamine synthetase shows more stringent selection behavior compared to CHO wild-type glutamine synthetase.

[0037] Bacterial glutamine synthetase and mammalian expression vector or host cell encoding bacterial glutamine synthetase Cell

[0038] The present invention demonstrates that certain bacterial glutamine synthetase genes unrelated to mammalian glutamine synthetase genes can be used as selection markers to generate high-yield and stable mammalian host cell pools or cell lines that express therapeutic proteins, such as therapeutic antibodies, and / or non-coding RNAs, such as siRNA or miRNA. This is the first time that prokaryotic glutamine synthetase variants have been successfully used as selection markers in mammalian cells, and surprisingly, glutamine synthetases from Providencia larvae and from Photorhabditis luminescens show more stringent selection behavior in CHO cells due to reduced activity compared to CHO wild-type glutamine synthetase, and result in increased productivity in CHO cells compared to the use of CHO wild-type glutamine synthetase as a selection marker. After providing proof of principle that certain bacterial glutamine synthetase genes can be used as selection markers in mammalian cells, further bacterial glutamine synthetase genes can be identified. Further, point mutations in highly conserved amino acids in Providencia larvae glutamine synthetase were identified that showed prolonged selection stringency and improved antibody titers compared to wild-type Providencia larvae glutamine synthetase. Due to the conservation of these amino acids at least in Photorhabdus luminescens glutamine synthetase, it is expected that these point mutations in Photorhabdus luminescens glutamine synthetase will similarly show prolonged selection stringency and improved antibody titers compared to wild-type Photorhabdus luminescens glutamine synthetase.

[0039] More specifically, in a first aspect, the present invention relates to a mammalian expression vector comprising a polynucleotide encoding a bacterial glutamine synthetase as a selection marker, wherein the bacterial glutamine synthetase comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 1 ( Figure 8 In certain embodiments, the bacterial glutamine synthetase is derived from bacteria of the order Enterobacteriales and the family Morganellaceae. After transfection or transduction of a mammalian expression vector according to the present invention, the bacterial glutamine synthetase mediates increased selection stringency and / or genetic stability of stably co-integrated proteins and / or non-coding RNAs of interest in CHO cells compared to a CHO glutamine synthetase having the amino acid sequence of SEQ ID NO: 2 ( Fig. 9 In certain embodiments, the bacterial glutamine synthetase is derived from a Providencia species and / or comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1 ( Figure 8 In certain embodiments, the bacterial glutamine synthetase is derived from a Photorhabditis species and / or comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 14 ( Fig.10). In a preferred embodiment, the bacterial glutamine synthetase is a Providencia larvae glutamine synthetase or a Photorhabdus luminescens glutamine synthetase. Preferably, the glutamine synthetase is from a Providencia species, more preferably from Providencia larvae. Thus, the glutamine synthetase may be a Providencia larvae glutamine synthetase, in particular a bacterial glutamine synthetase comprising the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 1. In certain embodiments, the bacterial glutamine synthetase comprises an amino acid sequence having at least 85%, at least 90% and preferably at least 95% sequence identity with SEQ ID NO: 1. In another embodiment, the bacterial glutamine synthetase comprises an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 1, or the bacterial glutamine synthetase comprises an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 14, preferably, the bacterial glutamine synthetase comprises an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with the amino acid sequence of SEQ ID NO: 1. Thus, the bacterial glutamine synthetase may have the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 14.

[0040] The bacterial glutamine synthetase may further comprise a point mutation that further weakens the glutamine synthetase (e.g., E130X and / or R345A) or increases catalytic activity (e.g., F226Y). In particular, the bacterial glutamine synthetase may have a point mutation in a highly conserved residue corresponding to position E130 of the Providencia larvae glutamine synthetase having an amino acid sequence of SEQ ID NO: 1. The point mutation at position E130 may be a substitution with any amino acid (X), i.e., E130 may be mutated to any amino acid except E (SEQ ID NO: 3). Preferably, the mutation in the amino acid position corresponding to E130 is a substitution with an aromatic or hydrophobic amino acid, more preferably, the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid selected from Y, W, F, A, G, V, L, M and I. Therefore, substitution for amino acids that do not contain polar, acidic or basic side chains is preferred. In certain embodiments, the mutation is E130F, E130G or E130A, more preferably E130F or E130G (E130F / G) (SEQ ID NO:4 or SEQ ID NO:5, respectively). As used herein, "X" refers to any amino acid, wherein reference to a mutation as E130X specifies that X is any amino acid other than the original amino acid, i.e., E (Glu, glutamic acid). Without being bound by theory, substitution of the highly conserved glutamic acid (E) corresponding to amino acid position E130 in SEQ ID NO:1 results in attenuation of the bacterial glutamine synthetase, wherein attenuation in this context means a decrease in enzymatic activity. Alternatively or in addition, the bacterial glutamine synthetase may have a point mutation in a highly conserved residue corresponding to position F226 of the Providencia larvae glutamine synthetase having the amino acid sequence of SEQ ID NO:1. The point mutation corresponding to amino acid position F226 of SEQ ID NO:1 is a substitution with the amino acid Y (Tyr, tyrosine), also referred to as F226Y. Without being bound by theory, it is believed that replacing the highly conserved phenylalanine (F) corresponding to amino acid position F266 in SEQ ID NO:1 with Y increases the catalytic activity of glutamine synthetase. Such mutations that increase the catalytic activity of glutamine synthetase can be advantageously combined with mutations that further weaken glutamine synthetase. In certain embodiments, the mutation is E130X and / or F226Y, wherein X is any amino acid or as specified above in this paragraph. More preferably, the mutation is E130X or E130X and F226Y. In a specific embodiment, the mutation is E130F / G or E130F / G and F226Y. Alternatively or in addition, the bacterial glutamine synthetase can have a point mutation in a highly conserved residue corresponding to position R345 of the Providencia larvae glutamine synthetase having the amino acid sequence of SEQ ID NO:1.The point mutation corresponding to the amino acid position R345 of SEQ ID NO: 1 is a substitution with amino acid A (Ala, alanine), also referred to as R345A, or alternatively with another amino acid with an aliphatic side chain, such as glycine (G), valine (V), leucine (L) or isoleucine (I), preferably glycine (G). Without being bound by theory, the substitution of the highly conserved arginine (R) corresponding to the amino acid position R345 in SEQ ID NO: 1 leads to a weakening of the bacterial glutamine synthetase, wherein weakening in this context means a reduction in enzymatic activity. Optionally, the bacterial glutamine synthetase may further comprise a point mutation F226Y. Therefore, in certain embodiments, the mutation is E130X and / or R345A (or G, V, L or I), optionally further comprising F226Y, wherein X is any amino acid or as specified above in this paragraph. Preferably, the mutation is E130F / G and / or R345A, optionally further comprising F226Y, such as E130F / G and R345A, optionally further comprising F226Y, or preferably E130F / G or R345A, optionally further comprising F226Y.

[0041] In certain embodiments, the bacterial glutamine synthetase comprises an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, and comprises a mutation selected from E130X, F226Y, R345A (or G, V, L or I), and combinations thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic and / or hydrophobic amino acid, more preferably wherein the aromatic and / or hydrophobic amino acid is selected from Y, W, F, A, G, V, L, M and I. In certain embodiments, the mutation is E130X and / or F226Y, and wherein E130X is E130F, E130G or E130A, more preferably E130F or E130G (E130F / G). As used herein, the term "mutation of E130X, F226Y, R345A and combinations thereof" means at least one mutation of E130X and / or F226Y and / or R345A, i.e. (1) E130X or F226Y or R345A; or (2) E130X and F226Y, or R345A and F226Y, or E130X and R345A; or (3) E130X and F226Y and R345A. Preferably, the mutation is (i) E130X or (ii) E130X and F226Y or (iii) R345A or (iv) R345A and F226Y, wherein X is as described herein.

[0042] In certain embodiments, the bacterial glutamine synthetase comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 14, and comprises a mutation selected from E130X, F226Y, R345A (or G, V, L or I), and combinations thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic and / or hydrophobic amino acid, more preferably selected from Y, W, F, A, G, V, L, M and I. Preferably, the amino acid sequence has at least 96%, preferably at least 98%, preferably at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 14, even more preferably, the amino acid sequence has the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 14, further comprising a mutation as disclosed herein, for example as exemplified in the amino acid sequences of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 20, 21, 22 and 29 (based on SEQ ID NO: 1) or SEQ ID NO: 23, 24, 25, 26, 27, 28 and 30 (based on SEQ ID NO: 14), preferably as in SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 20 and 21 (based on SEQ ID NO: 1) or SEQ ID NO: 23, 24, 25, 26 and 28 (based on SEQ ID NO: 14). In certain embodiments, the bacterial glutamine synthetase comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1, and comprises a mutation selected from E130X, F226Y, R345A (or G, V, L or I), and combinations thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic and / or hydrophobic amino acid, more preferably selected from Y, W, F, A, G, V, L, M and I. In certain embodiments, the mutation in the bacterial glutamine synthetase having at least 95% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 14 is E130X and / or F226Y, and wherein E130X is E130F, E130G or E130A, more preferably E130F or E130G (E130F / G). In certain embodiments, the mutation is E130X and / or F226Y and / or R345A, and wherein E130X is E130F, E130G or E130A, more preferably E130F or E130G (E130F / G).Thus, the bacterial glutamine synthetase may comprise the mutation (1) E130X or F226Y or R345A; or (2) E130X and F226Y, or R345A and F226Y, or E130X and R345A; or (3) E130X and F226Y and R345A. Preferably, the mutation is E130X or R345A and optionally F226Y, i.e. (i) E130X or (ii) E130X and F226Y or (iii) R345A or (iv) R345A and F226Y. As used herein, the term "mutation E130X and / or F226Y" means mutation E130X or F226Y or E130X and F226Y. More preferably, the mutation is E130X or E130X and F226Y. As used herein, the term mutation "F226Y and / or R345A" means the mutations F226Y or R345A or F226Y and R345A, preferably R345A or F226Y and R345A.

[0043] The mammalian expression vector according to the invention is used to express heterologous sequences in mammalian cells, i.e., it is suitable for expression in mammalian cells (e.g., mammalian cells), i.e., bacterial glutamine synthetase, and preferably further expression of proteins and / or non-coding RNAs of interest. Therefore, the mammalian expression vector according to the invention is characterized in that it comprises a polynucleotide encoding a bacterial glutamine synthetase operably linked to a mammalian promoter. Typically, the mammalian expression vector comprises an expression cassette comprising a polynucleotide encoding a bacterial glutamine synthetase operably linked to a mammalian promoter (e.g., a CMV promoter or an SV40 promoter). Mammalian promoters regulate transcription in mammalian cells, in particular mammalian promoters regulate transcription in mammalian cells. Exemplary mammalian promoters are (but are not limited to) the simian virus 40 early promoter (SV40), the cytomegalovirus immediate early promoter (CMV), the human ubiquitin C promoter (UBC), the human elongation factor 1 alpha promoter (EF1A), the mouse phosphoglycerate kinase 1 promoter (PGK), and the chicken β-actin promoter (CAGG) coupled to the CMV early enhancer. Mammalian expression vectors may further comprise bacterial sequences, such as origins of replication and resistance genes for amplification of the vector in bacterial cells.

[0044] The mammalian expression vector generally further comprises at least one polynucleotide encoding a protein of interest and / or a non-coding RNA, preferably an expression cassette comprising at least one polynucleotide encoding a protein of interest and / or a non-coding RNA. The polynucleotide encoding a protein of interest and / or a non-coding RNA is operably linked to a mammalian promoter. The protein of interest and / or the non-coding RNA and the bacterial glutamine synthetase can be encoded by the same (polycistronic) or separate expression cassettes. Preferably, the protein of interest and / or the non-coding RNA and the bacterial glutamine synthetase are encoded by at least two separate expression cassettes or at least two separate mRNA encodings. The present invention does not encompass fusion proteins of the protein of interest and bacterial glutamine synthetase or its parts. In certain embodiments, the non-coding RNA is RNA mediated by RNA interference (RNAi), such as miRNA, siRNA, lncRNA or shRNA.

[0045] As used herein, the term "expression cassette" is a different component of DNA, particularly vector DNA, consisting of one or more coding polynucleotide sequences and regulatory sequences that control their expression in transfected or transduced cells. The expression cassette comprises at least three components: a promoter sequence, an open reading frame, and a termination sequence. In mammalian expression vectors comprising polynucleotides encoding a protein of interest, the termination sequence is referred to as a 3' untranslated region and typically contains a polyadenylation site. The expression cassette directs the cell's machinery to prepare RNA, and therefore may also be referred to as a transcription cassette. RNA may be coding RNA, further processed into mRNA encoding a protein sequence such as glutamine synthetase or a protein of interest, or RNA may be non-coding RNA, such as RNA interference (RNAi)-mediated RNA, such as miRNA, siRNA, lncRNA, or shRNA.

[0046] The protein of interest can be any protein, but is typically a therapeutic protein. As used herein, the term "therapeutic protein" refers to a protein that can be used in medical treatments of humans and / or animals. These include, but are not limited to, cytokines, growth factors, hormones, coagulation factors, vaccines, interferons, fusion proteins, antibodies, antibody-derived molecules, and antibody mimics. In certain embodiments, the therapeutic protein is selected from cytokines, hormones, fusion proteins, antibodies, antibody-derived molecules, and antibody mimics.

[0047] In certain embodiments, the protein of interest is an antibody. In the case where the protein of interest is an antibody, the mammalian expression vector comprises a polynucleotide comprising a coding sequence of an antibody heavy chain variable region and / or a coding sequence of an antibody light chain variable region. In certain embodiments, the mammalian expression vector comprises a polynucleotide comprising a coding sequence of an antibody heavy chain and / or a coding sequence of a light chain. Therefore, the polynucleotide comprising the coding sequence of the heavy chain variable region and the polynucleotide comprising the coding sequence of the light chain variable region can be expressed on the same mammalian expression vector, or on a separate mammalian expression vector. The expression vector may comprise a polycistronic expression cassette, such as a bicistronic expression cassette and / or a multiple expression cassette. The polycistronic expression cassette comprises more than one open reading frame, which is separated by a sequence encoding an RNA element that allows translation initiation, such as an internal ribosome entry site (IRES). In a polycistronic expression cassette, two or more open reading frames are under the control of the same promoter. Therefore, a polynucleotide encoding at least one heavy chain variable region and a polynucleotide encoding at least one light chain variable region can be expressed in the same expression cassette (e.g., separated by an IRES sequence) or expressed by two separate expression cassettes. In addition, bacterial glutamine synthetase and the protein of interest and / or non-coding RNA can be expressed by the same or separate expression cassettes. In the case where the protein of interest is an antibody, bacterial glutamine synthetase and a polynucleotide encoding at least one variable region of a heavy chain and / or a polynucleotide encoding at least one variable region of a light chain can be expressed by the same or separate expression cassettes or a mixture thereof.

[0048] In a preferred embodiment, the mammalian expression vector is used for stable integration into the genome of the host cell (e.g., for stable transfection), and the integration portion of the vector comprises a polynucleotide encoding a bacterial glutamine synthetase and at least one polynucleotide encoding a protein of interest and / or a non-coding RNA. The mammalian expression vector according to the present invention, preferably the mammalian expression vector according to the present invention, is a plasmid, a bacterial artificial chromosome (BAC) or a viral vector. The plasmid, bacterial artificial chromosome (BAC) or a viral vector (e.g., a lentiviral vector) can be introduced into a mammalian host cell (e.g., a mammalian host cell) via transfection or transduction, respectively, and preferably stably integrated into the host cell genome. Suitable plasmids BACs or viral vectors are known to those skilled in the art, and the plasmid may further comprise a transposon recognition sequence upstream and downstream of a polynucleotide encoding a bacterial synthetase as a selection marker and optionally at least one polynucleotide encoding a protein of interest and / or a non-coding RNA.

[0049] Preferred proteins of interest are antibodies, including fragments and derivatives thereof. Typically, antibodies are monospecific, but antibodies can also be multispecific. Therefore, the present invention can be used to produce monospecific antibodies, multispecific antibodies or fragments thereof, preferably antibodies (monospecific), bispecific antibodies, trispecific antibodies or fragments thereof, preferably antigen-binding fragments thereof. Exemplary antibodies within the scope of the present invention include, but are not limited to, anti-CD2, anti-CD3, anti-CD20, anti-CD22, anti-CD30, anti-CD33, anti-CD37, anti-CD40, anti-CD44, anti-CD44v6, anti-CD49d, anti-CD52, anti-EGFR1 (HER1), anti-EGFR2 (HER2), anti-GD3, anti-IGF, anti-VEGF, anti-TNFα, anti-IL2, anti-IL-5R or anti-IgE antibodies, and are preferably selected from anti-CD20, anti-CD33, anti-CD37, anti-CD40, anti-CD44, anti-CD52, anti-HER2 / neu (erbB2), anti-EGFR, anti-IGF, anti-VEGF, anti-TNFα, anti-IL2 and anti-IgE antibodies.

[0050] The term "antibody", "antibodies" or "immunoglobulin" is used in the broadest sense herein and covers various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies) and antibody fragments, as long as they show the desired antigen binding activity. There are various classes of immunoglobulins: IgA, IgD, IgE, IgG, IgM, IgY, IgW. Preferably, the antibody is an IgG antibody, more preferably an IgG1 or IgG4 antibody.

[0051] Antibodies can be of any species, and include chimeric antibodies and humanized antibodies. "Chimeric" antibodies are molecules in which antibody domains or regions are derived from different species. For example, the variable regions of heavy and light chains can be derived from rat or mouse antibodies, and the constant regions can be derived from human antibodies. In "humanized" antibodies, only the minimum sequence is derived from non-human species. Usually, only the CDR amino acid residues of human antibodies are replaced by CDR amino acid residues of non-human species such as mice, rats, rabbits or llamas. Sometimes, a few key framework amino acid residues that have an impact on antigen binding specificity and affinity are also replaced by non-human amino acid residues.

[0052] Generally, an antibody is a tetrameric polypeptide consisting of two pairs of heterodimers, each of which is formed by a heavy chain and a light chain. Stabilization of both heterodimers and tetrameric polypeptide structures occurs via interchain disulfide bridges. Each chain consists of a domain called an "immunoglobulin domain" or "immunoglobulin region", whereby the terms "domain" or "region" are used interchangeably. Each domain contains about 70-110 amino acids and forms a compact three-dimensional structure. Both the heavy chain and the light chain contain a "variable domain" or "variable region" with less conserved sequences at their N-terminal ends, which is responsible for antigen recognition and binding. The variable region of the light chain is also referred to as "VL", while the variable region of the heavy chain is referred to as "VH".

[0053] "Antibody fragment" or "antigen-binding fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments. A Fab fragment consists of the variable regions of two chains linked together by adjacent constant regions. These fragments can be formed from conventional antibodies by protease digestion, such as with papain, but similarly, Fab fragments can also be produced by genetic engineering. Further antibody fragments include F(ab')2 fragments, which can be prepared by proteolytic cleavage with pepsin.

[0054] Genetic engineering methods can be used to produce shortened antibody fragments consisting only of the variable regions of heavy chain (VH) and light chain (VL). These are referred to as Fv fragments (variable fragments = fragments of variable parts). Since these Fv fragments lack the covalent bonding of the two chains by the cysteine ​​of the constant chain, Fv fragments are often stable. It is advantageous to connect the variable regions of the heavy chain and light chain by short peptide fragments of, for example, 10 to 30 amino acids, preferably 15 amino acids. In this way, a single peptide chain consisting of VH and VL connected by a peptide linker is obtained. This antibody protein is called single-chain Fv (scFv). Examples of scFv-antibody proteins are known to those skilled in the art. Therefore, antibody fragments and antigen-binding fragments further include Fv fragments and particularly scFv.

[0055] In recent years, various strategies have been developed for the preparation of scFv as a multimer derivative. This is expected to result in recombinant antibodies with improved pharmacokinetic and biodistribution properties and increased binding affinity. In order to achieve the multimerization of scFv, scFv is prepared as a fusion protein with a multimerization domain. The multimerization domain can be, for example, the CH3 region of IgG or a coiled coil structure (helical structure), such as a leucine zipper domain. However, there are also strategies (such as double antibodies, three antibodies and five antibodies) in which the interaction between the VH / VL regions of scFv is used for multimerization. The double antibody referred to by the technician means a divalent homodimer scFv derivative. The shortening of the linker in the scFv molecule to 5-10 amino acids causes the formation of homodimers in which interchain VH / VL superposition occurs. Double antibodies can be stabilized by incorporating disulfide bridges in addition. The example of double antibody-antibody protein is known according to the prior art.

[0056] By minibodies the skilled person means bivalent homodimeric scFv derivatives. It consists of a fusion protein containing the CH3 region of an immunoglobulin, preferably IgG, most preferably IgG1 as a dimerization region, which is connected to the scFv via a hinge region (e.g. also from IgG1) and a linker region. Examples of minibodies - antibody proteins are known from the prior art.

[0057] By triabodies, the skilled person means: trivalent homotrimeric scFv derivatives. ScFv derivatives in which VH-VL are directly fused without a linker sequence leading to the formation of trimers.

[0058] Technicians are also familiar with so-called mini antibodies, which have a divalent, trivalent or tetravalent structure and are derived from scFv. Multimerization is carried out by dimeric, trimeric or tetrameric coiled-coil structures. In a preferred embodiment of the present invention, the gene of interest encodes any desired polypeptide mentioned above, preferably a monoclonal antibody, a derivative thereof or a fragment thereof.

[0059] Further contemplated are single domain antibodies (sdAbs), also known as nanobodies, which are antibody fragments of a single monomeric variable antibody domain. Single domain antibodies are typically produced from camelids (V H H fragment) or cartilaginous fish (V NAR The heavy chain antibody found in the fragment was modified.

[0060] The immunoglobulin fragment consisting of the CH2 and CH3 domains of the antibody heavy chain is called "Fc fragment", "Fc region" or "Fc" due to its tendency to crystallize (Fc = fragment crystallizable). These can be formed from conventional antibodies by protease digestion, for example with papain or pepsin, but can also be produced by genetic engineering. The N-terminal part of the Fc fragment may differ depending on how many amino acids are still present in the hinge region.

[0061] Antibodies comprising an Fab and an Fc region may also be referred to as full-length antibodies. Full-length antibodies may be monospecific antibodies and multispecific antibodies. Multispecific antibodies are antibodies having at least two different antigen binding sites, each of which binds to a different epitope. Multispecific antibodies include bispecific antibodies and trispecific antibodies. Bispecific antibodies have two different binding sites. Multispecific antibodies also include antibody forms other than full-length antibodies, such as antibody-derived molecules.

[0062] Bispecific antibodies usually combine antigen binding specificity for target cells (e.g., malignant B cells) and effector cells (e.g., T cells, NK cells, or macrophages) in one molecule. Exemplary bispecific antibodies (but not limited thereto) are bispecific antibodies, BiTE (bispecific T cell adapter) formats, and DART (dual affinity retargeting) formats. The bispecific format separates the homologous variable domains of the heavy and light chains of two antigen binding specificities on two separate polypeptide chains, wherein the two polypeptide chains are non-covalently bound. The DART format is based on the bispecific format, but it provides additional stability through a C-terminal disulfide bridge. Trispecific antibodies are monoclonal antibodies combining three antigen binding specificities. They can be constructed based on bispecific antibody technology, which reconfigures the antigen recognition domains of two different antibodies into a bispecific molecule. For example, trispecific antibodies targeting CD38 on cancer cells and CD3 and CD28 on T cells have been generated. Multispecific antibodies are particularly difficult to produce with high product quality.

[0063] As used herein, the term "antibody-derived molecule" refers to any molecule comprising at least an antigen-binding portion structurally related to an antibody. It includes full-length monospecific antibodies or bispecific antibodies further modified with additional antigen-binding portions, or smaller antibody forms including the antibody forms described herein.

[0064] As used herein, the term "antibody mimetic" refers to a protein that binds to a specific antigen in a manner similar to an antibody, but is structurally unrelated to an antibody. Antibody mimetic includes, but is not limited to, anticalins, affibodies, adnectins, monoclonal antibodies, DARPins, affimers, and affitins.

[0065] Single domain antibodies (sdAb) may also be referred to as nanobodies. It will be appreciated by those skilled in the art that a protein may comprise more than one antigen binding domain and may therefore be multivalent, preferably divalent (e.g., a divalent sdAb or a divalent anticalin or any other divalent antibody mimetic).

[0066] Another preferred therapeutic protein is a fusion protein, such as an Fc fusion protein. Therefore, the present invention can be advantageously used to produce a fusion protein, such as an Fc fusion protein. The effector portion of the fusion protein can be the complete sequence of a natural or modified heterologous protein or any part of the sequence. The immunoglobulin protein constant domain sequence can be derived from any immunoglobulin subtype such as IgG1, IgG2, IgG3, IgG4, IgA1 or IgA2 subtype, or classification such as IgA, IgE, IgD or IgM. Preferentially, they are derived from human immunoglobulin, more preferably derived from human IgG, and even more preferably derived from human IgG1 and IgG2. The non-limiting examples of Fc fusion proteins are MCP1-Fc, ICAM-Fc, EPO-Fc and scFv fragments etc. coupled with the CH2 domains of the heavy chain immunoglobulin constant region comprising an N-linked glycosylation site. By introducing the CH2 domain of the heavy chain immunoglobulin constant region comprising an N-linked glycosylation site into another expression construct comprising, for example, other immunoglobulin domains, enzymatically active protein portions or effector domains, an Fc fusion protein can be constructed by genetic engineering methods. Therefore, the Fc fusion protein according to the present invention also comprises a single-chain Fv fragment connected to the CH2 domain of the heavy chain immunoglobulin constant region comprising, for example, an N-linked glycosylation site.

[0067] The term "cytokine" refers to a small protein that is released by cells and acts as an intercellular medium, such as a small protein that affects the behavior of cells around the secreting cell. Cytokines can be secreted by immune cells or other cells such as T cells, B cells, NK cells and macrophages. Cytokines may involve intercellular signaling events, such as autocrine signaling, paracrine signaling and endocrine signaling. They may mediate a series of biological processes, including but not limited to immunity, inflammation and hematopoiesis. Cytokines can be chemokines, interferons, interleukins, lymphokines or tumor necrosis factors.

[0068] As used herein, "growth factor" refers to a protein or polypeptide capable of stimulating cell growth.

[0069] In a related aspect, the present invention further relates to the use of the mammalian expression vector of the present invention for expressing a protein and / or non-coding RNA of interest in mammalian cells, particularly rodent cells, such as CHO cells. The bacterial glutamine synthetase encoded by the mammalian expression vector serves as a selection marker in the mammalian cells.

[0070] In a second aspect, the present invention relates to a nucleic acid sequence comprising a polynucleotide encoding a bacterial glutamine synthetase operably linked to a mammalian promoter, the bacterial glutamine synthetase comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, optionally further comprising at least one polynucleotide encoding a protein of interest and / or non-coding RNA. The nucleic acid sequence may be part of the mammalian expression vector of the first aspect. Therefore, the embodiments and examples specified with respect to the first aspect are similarly applicable to this aspect. In particular, in certain embodiments, the bacterial glutamine synthetase comprises an amino acid sequence having at least 85%, at least 90% or at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1, and comprises a mutation selected from E130X, F226Y, R345A and a combination thereof (e.g., E130X and / or F226Y), wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, the amino acid more preferably being selected from Y, W, F, A, G, V, L, M and I. Preferably, the mutation is E130X and / or F226, and E130X is E130F or E130G; or the mutation is F226Y and / or R345A; or the mutation is E130X and / or R345A, optionally further comprising the mutation F226Y.

[0071] In yet a third aspect, the present invention relates to a bacterial glutamine synthetase comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, and comprising a mutation selected from E130X, F226Y, R345A and combinations thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, more preferably selected from Y, W, F, A, G, V, L, M and I. In certain embodiments, the present invention relates to a bacterial glutamine synthetase, e.g. from Providencia larvae, comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1, and comprising a mutation selected from E130X, F226Y, R345A and combinations thereof (e.g. E130X and / or F226Y), wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, more preferably selected from Y, W, F, A, G, V, L, M and I; or a bacterial glutamine synthetase comprising an amino acid sequence identical to SEQ ID NO: 1 or SEQ ID NO: 2. NO:14 amino acid sequence having at least 95% sequence identity, and mutations E130X and / or F226Y and / or R345A, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, the amino acid more preferably being selected from Y, W, F, A, G, V, L, M and I. Preferably, the mutation is E130X and / or F226, and E130X is E130F or E130G; or the mutation is F226Y and / or R345A; or the mutation is E130X and / or R345A, optionally further comprising mutation F226Y, preferably E130X or R345A, optionally further comprising mutation F226Y. The embodiments and examples specified with respect to the first and second aspects apply similarly to this aspect.

[0072] In a fourth aspect, the present invention relates to a kit comprising an expression vector according to the present invention and optionally a cell culture medium without glutamine.

[0073] In a fifth aspect, the present invention relates to the use of bacterial glutamine synthetase as a selection marker in mammalian cells. The bacterial glutamine synthetase is as further specified as disclosed in relation to the first aspect above. More specifically, the bacterial glutamine synthetase is derived from Enterobacteriales and Morganellaceae, preferably Providencia species or Photorhabdus species, more preferably Providencia larvae or Photorhabdus luminescens, even more preferably Providencia larvae. Preferably, the bacterial glutamine synthetase comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 1. In certain embodiments, the bacterial glutamine synthetase comprises an amino acid sequence having at least 85%, at least 90% and preferably at least 95% sequence identity with SEQ ID NO: 1. In other embodiments, the bacterial glutamine synthetase comprises an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1, or an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the amino acid sequence of SEQ ID NO: 14. The bacterial glutamine synthetase mediates increased stringency of selection and / or genetic stability of stably co-integrated proteins and / or non-coding RNAs of interest in CHO cells after transfection or transduction of a mammalian expression vector comprising the bacterial glutamine synthetase, compared to a CHO glutamine synthetase having the amino acid sequence of SEQ ID NO: 2. In a preferred embodiment, the bacterial glutamine synthetase is derived from a Providencia species and / or comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1; more preferably, the bacterial glutamine synthetase is a Providencia larvae glutamine synthetase. In another preferred embodiment, the bacterial glutamine synthetase is derived from a Photorhabdus species and / or comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 14; more preferably, the bacterial glutamine synthetase is Photorhabdus luminescens glutamine synthetase. The amino acid sequences of Providencia larvae glutamine synthetase (SEQ ID NO: 1) and Photorhabdus luminescens glutamine synthetase (SEQ ID NO: 14) have 87.2% sequence identity (see Table B).

[0074] Bacterial glutamine synthetase can further comprise point mutations that further weaken glutamine synthetase (e.g., E130X and / or R345A) or increase catalytic activity (e.g., F226Y). In particular, bacterial glutamine synthetase can have a point mutation in a highly conserved residue at position E130 corresponding to the amino acid sequence of Providencia larvae glutamine synthetase with SEQ ID NO: 1. The point mutation at position E130 can be a substitution with any amino acid (X), preferably, the mutation in the amino acid position corresponding to E130 is a substitution with an aromatic or hydrophobic amino acid, such as a substitution with an aromatic or hydrophobic amino acid selected from Y, W, F, A, G, V, L, M and I. In certain embodiments, the mutation is E130F, E130G or E130A, more preferably E130F or E130G (E130F / G) (SEQ ID NO: 4 or SEQ ID NO: 5, respectively). Alternatively or in addition, the bacterial glutamine synthetase may have a point mutation in a highly conserved residue corresponding to position F226 of the Providencia larvae glutamine synthetase having the amino acid sequence of SEQ ID NO: 1, wherein the point mutation is a substitution with an amino acid Y (Tyr, tyrosine), also referred to as F226Y. In certain embodiments, the mutation is E130X and / or F226Y, wherein X is any amino acid or as specified above in this paragraph. More preferably, the mutation is E130X or E130X and F226Y. In a specific embodiment, the mutation is E130F / G or E130F / G and F226Y. Alternatively or in addition, the bacterial glutamine synthetase may have a point mutation in a highly conserved residue corresponding to position R345 of the Providencia larvae glutamine synthetase having the amino acid sequence of SEQ ID NO: 1. The point mutation corresponding to the amino acid position R345 of SEQ ID NO: 1 is a substitution with an amino acid A (Ala, alanine), also referred to as R345A, or alternatively with another amino acid with an aliphatic side chain, such as glycine (G), valine (V), leucine (L) or isoleucine (I), preferably glycine (G). Without being bound by theory, substitution of the highly conserved arginine (R) corresponding to the amino acid position R345 in SEQ ID NO: 1 results in a weakening of the bacterial glutamine synthetase, wherein weakening in this context means a reduction in enzymatic activity. Optionally, the bacterial glutamine synthetase may further comprise a point mutation F226Y. Thus, in certain embodiments, the mutation is E130X and / or R345A (or G, V, L or I), optionally further comprising F226Y, wherein X is any amino acid or as specified above in this paragraph.Preferably, the mutation is E130F / G and / or R345A, optionally further comprising F226Y, such as E130F / G and R345A, optionally further comprising F226Y, or preferably E130F / G or R345A, optionally further comprising F226Y. Preferably, the bacterial glutamine synthetase comprises an amino acid having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 1, further comprising a point mutation as indicated above.

[0075] In a preferred embodiment, the bacterial glutamine synthetase comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 14, and comprises a mutation selected from E130X, F226Y, R345A (or G, V, L or I) and combinations thereof (e.g., E130X and / or F226Y), wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic and / or hydrophobic amino acid, more preferably selected from Y, W, F, A, G, V, L, M and I. Preferably, the amino acid sequence has at least 96%, preferably at least 98%, preferably at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 14, even more preferably, the amino acid sequence has the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 14, further comprising a mutation as disclosed herein, for example as exemplified in the amino acid sequences of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 20, 21, 22 and 29 (based on SEQ ID NO: 1) or SEQ ID NO: 23, 24, 25, 26, 27, 28 and 30 (based on SEQ ID NO: 14), preferably SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 20 and 21 (based on SEQ ID NO: 1) or SEQ ID NO: 23, 24, 25, 26 and 28 (based on SEQ ID NO: 14). In certain embodiments, mutation is E130X and / or F226Y, and preferably wherein E130X is E130F, E130G or E130A, more preferably E130F or E130G (E130F / G). In certain embodiments, mutation is F226Y and / or R345A, more preferably R345A or R345A and F226Y. In certain embodiments, mutation is E130X and / or R345A (or G, V, L or I), optionally further comprising F226Y, wherein X is any amino acid or as specified above in this paragraph. Preferably, mutation is E130F / G and / or R345A, optionally further comprising F226Y, such as E130F / G and R345A, optionally further comprising F226Y, or preferably E130F / G or R345A, optionally further comprising F226Y.

[0076] In the sixth aspect, the present invention relates to a mammalian host cell, which comprises a mammalian expression vector of the present invention (first aspect), a nucleic acid sequence of the present invention (second aspect) or a nucleic acid sequence encoding a bacterial glutamine synthetase of the present invention (third aspect). The mammalian host cell can be any host cell, provided that the host cell is an immortalized cell rather than a primary cell. In certain embodiments, the mammalian host cell is a mouse, human or rodent cell, more preferably a rodent cell, and even more preferably a CHO cell. In addition, the mammalian host cell is preferably a GS knockout cell (GS knockout mutant) host cell. As used herein, the term "GS knockout cell" refers to a cell in which the endogenous GS gene has been knocked out, i.e., deleted or destroyed, resulting in a cell in which the GS enzyme function is destroyed. Such cells may be referred to as GS- / - or GS- / + cells, depending on whether two or only one allele has been deleted or destroyed. Extracellular glutamine supplementation or the GS gene introduced by the expression vector is essential for the cell survival of the GS knockout cell. In a preferred embodiment, the mammalian host cell is a CHO-K1 cell, more preferably a CHO-K1-GS (GS- / -) cell. In certain embodiments, the mammalian host cell is a monoclonal cell line generated by single cell cloning and clonal expansion steps.Preferably, the mammalian host cell comprises a polynucleotide encoding a bacterial glutamine synthetase and at least one polynucleotide encoding a protein and / or non-coding RNA of interest co-integrated into the host cell genome.

[0077] Methods for preparing cell lines or producing proteins

[0078] In the seventh aspect, the present invention relates to a method for preparing a cell stably expressing a protein and / or non-coding RNA of interest, comprising (a) introducing an expression vector according to the present invention (the first aspect) or a nucleic acid according to the present invention (the second aspect) into a mammalian host cell, wherein the expression vector or nucleic acid comprises a polynucleotide encoding a bacterial glutamine synthetase and at least one polynucleotide encoding a protein and / or non-coding RNA of interest; and (b) culturing the mammalian host cell in a glutamine-free medium under conditions that select for bacterial glutamine synthetase, wherein at least one polynucleotide encoding a protein and / or non-coding RNA of interest is co-integrated with a polynucleotide encoding a bacterial glutamine synthetase into the host cell genome. Optionally, the method may further comprise the steps of culturing the resulting cell pool stably expressing the protein and / or non-coding RNA of interest selected in step (b) and / or isolating a cell pool stably expressing the protein and / or non-coding RNA of interest. A cell stably expressing a protein and / or non-coding RNA of interest means that the polynucleotide encoding the protein and / or non-coding RNA of interest is stably integrated into the genome of the host cell, and the protein and / or non-coding RNA of interest is stably expressed, i.e., over an extended period of time, e.g., at least 40 days, preferably several months or years.

[0079] The mammalian expression vector or nucleic acid can be a plasmid, a bacterial artificial chromosome (BAC) or a viral vector. Therefore, the mammalian expression vector or nucleic acid of the present invention can be introduced by transfection or transduction, respectively. Preferably, the mammalian expression vector or nucleic acid is a plasmid. More preferably, the mammalian expression vector or nucleic acid is introduced by stable transfection. The method of transducing or transfecting the mammalian expression vector or nucleic acid into a mammalian cell is well known in the art, and includes chemical means such as calcium phosphate precipitation and lipofection and physical means such as electroporation. The polynucleotide encoding bacterial glutamine synthetase and the polynucleotide encoding the protein of interest and / or non-coding RNA are operably connected to a mammalian promoter, and are therefore suitable for expression in a mammalian host cell.

[0080] The method of the present invention may further include separating a single clone for clonal expansion to prepare a step (c) of a monoclonal cell line. It will be appreciated by those skilled in the art that transfection or transduction often requires a large number of cells, resulting in heterogeneous recombinant cell pools with, for example, different integration site populations. In order to generate a clonal cell line, the cell pool is diluted or sorted for single cell separation (monoclonal), and each single clone is subjected to clonal expansion to prepare a monoclonal cell line. As used herein, the term "cell line" refers to a cell colony derived from a single cell clone and can grow indefinitely. Therefore, it is also referred to as a monoclonal cell line. Therefore, cell lines are genetically stable, and therefore the characteristics of cell lines should not change over a period of time. In particular, when cultivated under comparable conditions, phenotypic characteristics such as production levels (titer) and growth rate and density (VCD and maximum VCD), vigor, and the genetic integrity measured via copy number and DNA fingerprinting should be maintained.

[0081] The cell pool or monoclonal cell line prepared according to the method of the present invention can be further used for stable production of proteins of interest or stable production of non-coding RNA, such as RNA mediating RNAi, such as miRNA, siRNA, lncRNA or shRNA. RNAi is used for gene silencing, and therefore can be used to generate a cell pool or monoclonal cell line with a beneficial property for, for example, protein production. For example, host cell proteins (HCPs) that are difficult to remove can be silenced in a cell pool or a monoclonal cell line, or enzymes such as fucosyltransferases can be silenced to modify the glycosylation profile of a cell pool or a monoclonal cell line. In addition, CHO cells commonly used for large-scale industrial production are often transformed to improve their characteristics in the production process, or to promote the selection of recombinant cells. Such transformations include, but are not limited to, increasing resistance to apoptosis, reducing autophagy, increasing cell proliferation, changing the expression of cell cycle regulatory proteins, molecular chaperone transformation, the transformation of unfolded protein response (UPR), the transformation of secretory pathways and metabolic transformation. Such transformations can potentially be achieved using RNAi in mammalian host cells generated by the method of the present invention.

[0082] In a related eighth aspect, the present invention relates to a method for producing a protein of interest, comprising: (a) introducing a mammalian expression vector according to the invention or a nucleic acid according to the invention into a mammalian host cell, wherein the expression vector comprises a polynucleotide encoding a bacterial glutamine synthetase operably linked to a mammalian promoter and at least one polynucleotide encoding a protein of interest; (b) culturing the mammalian host cell in a glutamine-free medium under conditions that select for bacterial glutamine synthetase, wherein the at least one polynucleotide encoding the protein of interest is co-integrated with the polynucleotide encoding the bacterial glutamine synthetase into the host cell genome; (c) optionally isolating a single clone for clonal amplification to prepare a monoclonal cell line; (d) culturing the mammalian host cell under conditions that produce the protein of interest; and (e) harvesting and optionally purifying the protein of interest. The mammalian expression vector or nucleic acid of the invention can be introduced by transfection or transduction. Preferably, the mammalian expression vector or nucleic acid is introduced by stable transfection.

[0083] It will be appreciated by those skilled in the art that for mammalian expression vectors, usually only part of the vector is integrated into the genome of the host cell. Therefore, the integrated portion of the vector comprises a polynucleotide encoding a bacterial glutamine synthetase and at least one polynucleotide encoding a protein of interest and / or a non-coding RNA. In addition, the integrated portion of the mammalian expression vector of the present invention or the integrated nucleic acid sequence can be further amplified, for example, by increasing the concentration of a glutamine synthetase inhibitor, such as methionine sulfoximine (MSX). Amplification is optional, and due to the higher copy number of the polynucleotide encoding a protein of interest and / or a non-coding RNA, a higher productivity can be caused, because these become co-amplified with the bacterial glutamine synthetase. The method according to the present invention may include generating a cell pool or a monoclonal cell line. Further, the mammalian host cell generated according to the method of the present invention or the mammalian host cell according to the present invention can be further used to produce a protein of interest and / or a non-coding RNA or in a method for producing a protein of interest.

[0084] Thus, in a further ninth aspect, the present invention relates to a method for producing a protein of interest, comprising (a) providing a mammalian host cell according to the present invention or produced by a method according to the present invention, comprising a polynucleotide encoding a bacterial glutamine synthetase operably linked to a mammalian promoter and at least one polynucleotide encoding a protein of interest; (b) culturing the mammalian host cell under conditions such that the protein of interest is produced; and (c) harvesting and optionally purifying the protein of interest.

[0085] In a preferred embodiment of the method of the present invention, the mammalian host cell is a GS gene knockout cell. It will be understood by those skilled in the art that this refers to the endogenous GS gene, while the bacterial GS gene is present in the host cell after transfection or transduction of the mammalian expression vector or nucleic acid sequence of the present invention. The mammalian host cell (transfected or transduced with the mammalian expression vector or nucleic acid sequence of the present invention) is cultured in a medium without glutamine under conditions that select for bacterial glutamine synthetase in step (b). This may further include the addition of the GS inhibitor methionine sulfoximine (MSX).

[0086] In certain embodiments of the methods of the invention, cells (cell pools) or monoclonal cell lines are generated with increased stringency of selection and / or have increased genetic stability and / or have higher productivity compared to cells or cell lines generated with glutamine synthetase from Chinese hamster with the amino acid sequence of SEQ ID NO:2. Genetic stability can be quantified by measuring the copy number of the integrated transgene. Genetic stability is evaluated by measuring the copy number during extended culture time. In addition, genomic rearrangements are monitored via, for example, Southern blot analysis. The increase in selection stringency can be determined by the duration until >70% viability is reached.

[0087] The mammalian host cell can be any host cell, provided that the host cell is an immortalized cell rather than a primary cell. The method described herein is an in vitro method, and the mammalian host cell according to the present invention is used for in vitro use in cell culture. As used herein, the term "mammalian cell" refers to a mammalian cell line suitable for producing a product of interest, such as a heterologous protein of interest and / or a non-coding RNA, and may also be referred to as a "host cell" or "mammalian host cell". Mammalian cells are preferably transformed and / or immortalized cell lines. They are suitable for continuous passage in cell culture, preferably serum-free cell culture and / or preferably suspension culture, and do not include primary non-transformed cells or cells that are part of an organ structure.

[0088] Preferably, the mammalian host cell is a mouse, a human or a rodent cell, more preferably a rodent cell, even more preferably a CHO cell. Preferred mammalian cells for heterologous protein production are mouse cells, rodent cells or human cells. Preferred examples of mammalian cells or mammalian cell lines are CHO cells (e.g., DG44 and K1), NS0 cells, HEK293 cells (e.g., HEK293 cells and HEK293T cells) and BHK21 cells. Preferably, mammalian cells or mammalian cell lines are suitable for suspension growth. In a preferred embodiment, mammalian cells or mammalian cell lines are CHO cells. In certain embodiments, mammalian cells are HEK293 cells or CHO cells or cells derived from HEK293 cells or CHO cells, preferably, mammalian cells are CHO cells or CHO derived cells.

[0089] Suitable rodent cells can be, for example, hamster cells, particularly BHK21, BHK TK, CHO, CHO-K1, CHO-DXB11 (also referred to as CHO-DUKX or DuxB11), CHO-S cells and CHO-DG44 cells or derivatives / progeny of any such cell lines. Particularly preferred are CHO cells, such as CHO-DG44, CHO-K1 and BHK21, and even more preferred are CHO-DG44 and CHO-K1 cells. Most preferred are CHO-DG44 cells. Mammalian cells, particularly glutamine synthetase (GS) deficient derivatives of CHO-DG44 and CHO-K1 cells are also contemplated. In one embodiment of the invention, mammalian cells are Chinese hamster ovary (CHO) cells, preferably CHO-DG44 cells, CHO-K1 cells, CHO DXB11 cells, CHO-S cells, CHO GS deficient cells or derivatives thereof. Suitable human cells are HEK293 or HEK293T cells. The host cell may also be a murine cell, such as a murine myeloma cell, such as NS0 and Sp2 / 0 cells or a derivative / progeny of any such cell line.

[0090] In addition, the mammalian host cell is preferably a GS knockout cell (GS knockout mutant). As used herein, the term "GS knockout cell" refers to a cell in which the endogenous GS gene has been knocked out, i.e., deleted or destroyed, resulting in a cell in which the GS enzyme function is destroyed. Such cells may be referred to as GS- / - or GS- / + cells, depending on whether two or only one allele has been deleted or destroyed. Extracellular glutamine supplementation or the GS gene introduced by an expression vector is essential for the cell survival of the GS knockout cell. In a preferred embodiment, the mammalian host cell is a CHO-K1 cell, more preferably a CHO-K1-GS (GS- / -) cell.

[0091] Preferably, CHO cells that allow for efficient cell line development processes are metabolically engineered, for example by knockout of endogenous glutamine synthetase (GS), to facilitate selection with methionine sulfoximine (MSX).

[0092] Non-limiting examples of mammalian cells that can be used in the context of the present invention are also summarized in Table A. However, derivatives / progeny of these cells, other mammalian cells, including but not limited to human, mouse, rat, monkey and rodent cell lines, can also be used in the present invention, particularly for the production of biopharmaceutical proteins.

[0093] Table A: Exemplary mammalian production cell lines

[0094]

[0095]

[0096] 1 CAP (Amniotic Cell Production of CEVEC) cells are an immortalized cell line based on primary human amniotic cells. They are generated by transfecting these primary cells with a vector containing functional E1 and pIX of adenovirus 5. CAP cells allow the competitive and stable production of recombinant proteins with excellent biological activity and therapeutic efficacy due to authentic human post-translational modifications.

[0097] At the time of establishment, the cells are most preferably adapted and cultured completely under serum-free conditions and optionally in a medium that does not contain any proteins / peptides of animal origin. Commercially available culture media such as Ham's F12 (Sigma, Deisenhofen, Germany), RPMI-1640 (Sigma), Dulbecco's Modified Eagle's Medium (DMEM; Sigma), Minimum Essential Medium (MEM; Sigma), Iscove's Modified Dulbecco's Medium (IMDM; Sigma), CD-CHO (Invitrogen, Carlsbad, CA), serum-free CHO medium (Sigma), and protein-free CHO medium (Sigma) are exemplary of appropriate nutrient solutions. Any culture medium may be supplemented with various compounds, non-limiting examples of which are recombinant hormones and / or other recombinant growth factors (e.g., insulin, transferrin, epidermal growth factor, insulin-like growth factor), salts (e.g., sodium chloride, calcium, magnesium, phosphate), buffers (e.g., HEPES), nucleosides (e.g., adenosine, thymidine), glutamine, glucose or other equivalent energy sources, antibiotics, and trace elements, as needed. Any other necessary supplements may also be included at appropriate concentrations known to those skilled in the art.For growth and selection of genetically modified cells expressing a selectable gene, a suitable selective agent is added to the culture medium.

[0098] The protein of interest encoded by a mammalian expression vector or produced by the method of the present invention is preferably produced in CHO cells in cell culture. After expression, the recombinant protein is harvested and further purified. The antibody can be recovered from the culture medium as a secretory protein in the cell culture fluid (HCCF) of the harvest, or recovered from a cell lysate (i.e., a fluid containing the contents of the cell cracked by any means, including but not limited to the enzymatic, chemical, osmotic, mechanical and / or physical destruction of the cell membrane and optional cell wall), and purified using the technology described herein. According to the present invention, the method includes providing a cell culture fluid of the harvest, which contains a protein of interest such as an antibody as a raw material, wherein the HCCF is from a CHO cell culture. Preferably, a protein of interest, such as an antibody, is recovered from the cell culture fluid of the harvest after cell separation, such as by filtering and / or centrifugation. Therefore, in certain embodiments, harvesting includes centrifugation and / or filtering to produce a cell culture fluid of the harvest.

[0099] In view of the above, it should be understood that the present invention also covers the following technical solutions:

[0100] Technical solution 1 provides a mammalian expression vector (eg, a mammalian expression vector) comprising a polynucleotide encoding a bacterial glutamine synthetase as a selection marker, wherein the bacterial glutamine synthetase comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 1.

[0101] Technical solution 2 specifies, for the mammalian expression vector of technical solution 1, that the bacterial glutamine synthetase is derived from bacteria of the Enterobacteriales and Morganellaceae families.

[0102] Technical solution 3 specifies for the mammalian expression vector of technical solution 1 or 2, that the bacterial glutamine synthetase is derived from a Providencia species or a Photorhabdus species, preferably wherein the bacterial glutamine synthetase is Providencia larvae glutamine synthetase or Photorhabdus luminescentus glutamine synthetase.

[0103] Technical solution 4 specifies, for the mammalian expression vector of any one of technical solutions 1 to 3, that the bacterial glutamine synthetase comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 1, and comprises a mutation selected from E130X, F226Y, R345A and a combination thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, and the amino acid is more preferably selected from Y, W, F, A, G, V, L, M and I.

[0104] Technical solution 5 specifies, for the mammalian expression vector of any one of technical solutions 1 to 4, that the bacterial glutamine synthetase comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 14, and comprises a mutation selected from E130X, F226Y, R345A and a combination thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, and the amino acid is more preferably selected from Y, W, F, A, G, V, L, M and I.

[0105] Technical solution 6 further specifies the mammalian expression vector of technical solution 4 or 5, wherein the mutation is E130X and / or F226Y and / or R345A, and wherein E130X is E130F or E130G.

[0106] Technical solution 7 further specifies the mammalian expression vector of any one of Technical Solutions 1 to 6, wherein the polynucleotide encoding the bacterial glutamine synthetase is operably linked to a mammalian promoter.

[0107] Technical solution 8 further specifies a mammalian expression vector of any one of Technical Solutions 1 to 7, wherein the mammalian expression vector further comprises at least one polynucleotide encoding a protein and / or non-coding RNA of interest, preferably an expression cassette comprising at least one polynucleotide encoding a protein and / or non-coding RNA of interest.

[0108] Technical solution 9 further specifies a mammalian expression vector according to any one of Technical Solutions 1 to 8, wherein the protein of interest is a therapeutic protein, preferably selected from cytokines, hormones, fusion proteins, antibodies, antibody-derived molecules and antibody mimetics.

[0109] Technical solution 10 further specifies a mammalian expression vector according to technical solution 9, wherein the protein of interest is an antibody, preferably wherein the expression vector comprises a polynucleotide comprising a coding sequence of an antibody heavy chain variable region and / or a coding sequence of a light chain variable region.

[0110] Technical solution 11 further specifies a mammalian expression vector according to any one of technical solutions 8 to 10, wherein the mammalian expression vector comprises a polycistronic expression cassette and / or a multiple expression cassette, preferably wherein the expression vector comprises multiple expression cassettes.

[0111] Technical solution 12 further specifies a mammalian expression vector of any one of technical solutions 8 to 11, wherein the mammalian expression vector is used for stable transfection, and the integration portion of the vector comprises a polynucleotide encoding a bacterial glutamine synthetase and at least one polynucleotide encoding a protein and / or non-coding RNA of interest.

[0112] Technical solution 13 further specifies a mammalian expression vector according to any one of Technical Solutions 1 to 12, wherein the mammalian expression vector is a plasmid, a bacterial artificial chromosome (BAC) or a viral vector.

[0113] Technical solution 14 provides a nucleic acid sequence comprising a polynucleotide encoding a bacterial glutamine synthetase operably linked to a mammalian promoter, optionally further comprising at least one polynucleotide encoding a protein and / or non-coding RNA of interest.

[0114] Technical solution 15 further specifies the nucleic acid sequence of technical solution 14, wherein the bacterial glutamine synthetase comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 1, and comprises a mutation selected from E130X, F226Y, R345A and a combination thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, and the amino acid is more preferably selected from Y, W, F, A, G, V, L, M and I.

[0115] Technical solution 16 further specifies the nucleic acid sequence of technical solution 15, wherein the bacterial glutamine synthetase comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 1, and comprises a mutation selected from E130X, F226Y, R345A and a combination thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, and the amino acid is more preferably selected from Y, W, F, A, G, V, L, M and I.

[0116] Technical solution 17 further specifies the nucleic acid sequence of technical solution 15, wherein the bacterial glutamine synthetase comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 14, and comprises a mutation selected from E130X, F226Y, R345A and a combination thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, and the amino acid is more preferably selected from Y, W, F, A, G, V, L, M and I.

[0117] Technical solution 18 further specifies the nucleic acid sequence of any one of technical solutions 15 to 17, wherein the mutation is E130X and / or F226 and / or R345A, and wherein E130X is E130F or E130G

[0118] Technical solution 19 provides a bacterial glutamine synthetase, which comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO: 1, and comprises a mutation selected from E130X, F226Y, R345A and a combination thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, and the amino acid is more preferably selected from Y, W, F, A, G, V, L, M and I.

[0119] Technical solution 20 provides a bacterial glutamine synthetase from Providencia larvae, comprising an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 1, and comprising a mutation selected from E130X, F226Y, R345A and a combination thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, and the amino acid is more preferably selected from Y, W, F, A, G, V, L, M and I.

[0120] Technical solution 21 provides a bacterial glutamine synthetase from luminous Photorhabditis elegans, comprising an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 14, and comprising a mutation selected from E130X, F226Y, R345A and a combination thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, and the amino acid is more preferably selected from Y, W, F, A, G, V, L, M and I.

[0121] Technical solution 22 provides a mammalian host cell, which comprises an expression vector of any one of Technical Solutions 1 to 13, a nucleic acid sequence of any one of Technical Solutions 14 to 18, or a nucleic acid sequence encoding a bacterial glutamine synthetase of any one of Technical Solutions 19 to 21, preferably wherein the mammalian host cell is a rodent cell, more preferably a CHO cell and / or (b) a GS gene knockout cell.

[0122] Technical solution 23 further specifies the mammalian host cell of technical solution 22, wherein it comprises a polynucleotide encoding a bacterial glutamine synthetase and at least one polynucleotide encoding a protein and / or non-coding RNA of interest co-integrated into the host cell genome.

[0123] Technical solution 24 provides a method for preparing cells that stably express a protein and / or non-coding RNA of interest, comprising (a) introducing an expression vector according to Technical Solutions 1 to 13 or a nucleic acid according to any one of Technical Solutions 14 to 18 into a mammalian host cell, such as a CHO cell, wherein the expression vector or nucleic acid comprises a polynucleotide encoding a bacterial glutamine synthetase and at least one polynucleotide encoding a protein and / or non-coding RNA of interest; and (b) culturing the mammalian host cell in a glutamine-free culture medium under conditions that select for bacterial glutamine synthetase, wherein the at least one polynucleotide encoding the protein and / or non-coding RNA of interest is co-integrated into the host cell genome with the polynucleotide encoding the bacterial glutamine synthetase.

[0124] Technical solution 25 further specifies the method of technical solution 24, which includes the step of (c) isolating a single clone for clonal expansion to prepare a monoclonal cell line.

[0125] Technical solution 26 provides a method for producing a protein of interest, which comprises (a) introducing a mammalian expression vector according to technical solutions 1 to 13 or a nucleic acid according to any one of technical solutions 14 to 18 into a mammalian host cell, preferably a mammalian host cell, such as a CHO cell, wherein the expression vector comprises a polynucleotide encoding a bacterial glutamine synthetase operably linked to a mammalian promoter and at least one polynucleotide encoding a protein of interest; (b) culturing the mammalian host cell in a glutamine-free medium under conditions that select for bacterial glutamine synthetase, wherein the at least one polynucleotide encoding the protein of interest is co-integrated with the polynucleotide encoding the bacterial glutamine synthetase into the host cell genome; (c) optionally isolating a single clone for clonal amplification to prepare a monoclonal cell line; (d) culturing the mammalian host cell under conditions for producing the protein of interest; and (e) harvesting and optionally purifying the protein of interest.

[0126] Technical solution 27 further specifies the method of any one of technical solutions 24 to 26, wherein the mammalian expression vector or nucleic acid is introduced by transfection or transduction.

[0127] Technical solution 28 further specifies the method of technical solution 27, wherein the mammalian expression vector or nucleic acid is introduced by stable transfection.

[0128] Technical solution 29 provides a method for producing a protein of interest, which comprises (a) providing a mammalian host cell of technical solution 22 or 23, which comprises a polynucleotide encoding a bacterial glutamine synthetase operably linked to a mammalian promoter and at least one polynucleotide encoding a protein of interest; (b) culturing the mammalian host cell under conditions for producing the protein of interest; and (c) harvesting and optionally purifying the protein of interest.

[0129] Technical solution 30 further specifies the method of any one of technical solutions 24 to 29, wherein (a) the mammalian host cell is a GS gene knockout cell; and / or (b) under the conditions of selecting bacterial glutamine synthetase in step (b), culturing the mammalian host cell in a glutamine-free culture medium includes adding the GS inhibitor methionine sulfoximine (MSX).

[0130] Technical solution 31 further specifies the method of any one of technical solutions 24 to 30, wherein the mammalian host cell is a rodent cell, preferably a CHO cell.

[0131] Technical solution 32 further specifies the method of any one of technical solutions 24 to 30, wherein the cells or cell lines are produced with increased selection stringency and / or have increased genetic stability and / or have higher productivity compared to cells or cell lines produced using glutamine synthetase from Chinese hamster having the amino acid sequence of SEQID NO: 2.

[0132] Technical solution 33 provides a kit comprising the expression vector of any one of Technical Solutions 1 to 13 and a cell culture medium that does not contain glutamine.

[0133] Technical solution 34 provides the use of bacterial glutamine synthetase as a selection marker in mammalian cells, preferably wherein the bacterial glutamine synthetase comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO:1.

[0134] Technical solution 35 further specifies the use of technical solution 34, wherein the bacterial glutamine synthetase is derived from bacteria of the Enterobacteriales and Morganellaceae, more preferably from Providencia species or Photorhabdus species, and even more preferably from larval Providencia or luminous Photorhabdus.

[0135] Technical solution 36 further specifies the use of technical solution 35, wherein the bacterial glutamine synthetase (a) is derived from a Providencia species and / or comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 1; more preferably wherein the bacterial glutamine synthetase is Providencia larvae glutamine synthetase.

[0136] Technical solution 37 further specifies the use of any one of technical solutions 34 to 36, wherein the bacterial glutamine synthetase comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 1, and comprises a mutation selected from E130X, F226Y, R345A and a combination thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, and the amino acid is more preferably selected from Y, W, F, A, G, V, L, M and I.

[0137] Technical solution 38 further specifies the use of technical solution 34, wherein the bacterial glutamine synthetase is derived from a species of the genus Photorhabdus and / or comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 1; more preferably wherein the bacterial glutamine synthetase is Photorhabdus luminescent glutamine synthetase.

[0138] Technical solution 39 further specifies the use of any one of technical solutions 34, 35 and 38, wherein the bacterial glutamine synthetase comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 14, and comprises a mutation selected from E130X, F226Y, R345A and a combination thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, and the amino acid is more preferably selected from Y, W, F, A, G, V, L, M and I.

[0139] Technical solution 40 further specifies the use of technical solution 37 or 39, wherein the mutation is E130X and / or F226Y and / or R345A, and wherein E130X is E130F or E130G.

[0140] Example

[0141] Linearization of plasmids for transfection

[0142] The plasmid used for stable transfection comprises a CMV-driven antibody transcription cassette, an ampicillin transgene, and a glutamine synthetase transgene as a metabolic selection marker. The plasmid is linearized using PvuI (single incision in the ampicillin transgene) for transfection. According to the manufacturer's protocol, a restriction digest of 20 μg of plasmid DNA was performed with PvuI (NEB) at 37°C for 3 hours. The linearized plasmid DNA is purified (Qiagen Plasmid Maxi Kit) according to the manufacturer's protocol. Final DNA concentration is determined via a Nanodrop spectrophotometer.

[0143] Host cell culture

[0144] CHO-K1-GS knockout cell line host cells with genomic knockout of the endogenous glutamine synthetase gene (also referred to as CHO-K1-GS KO or simply CHO-K1-GS) were cultured in host cell culture medium with added L-glutamine. The culture of host cells was started at an inoculation density of 3x10E05 cells / mL. Growth conditions were set at 36.5°C and 5% CO2 in a shaking incubator with 120 rpm in a shake flask. Cell density and viability were determined at Cedex Occurs in a cell counting analyzer.

[0145] Transfection of linearized plasmids in CHO

[0146] One day before transfection, host cells were seeded at a cell density of 0.8x10E06 cells / mL in a shake flask. On the day of transfection, cell density and viability were determined, and the amount of cells required for transfection was centrifuged at 750x G for 7 minutes. The supernatant was discarded. 10 μg of linearized plasmid DNA / transfection was used Transfection system (Invitrogen) and electroporation are carried out. Electroporation cuvette is equipped with 3mL electroporation buffer E2, and cells (5x10E6) are resuspended in 89μl buffer R, and mixed with 10μg linearized plasmid. Transfection is carried out using 1500 volts, 10mS and pulse 2. Transfected cells are transferred to 5ml preheated host cell culture medium in a T25ml flask, and accompanied by 8% CO2 and 37°C incubation for at least 24 hours.

[0147] Selection of stable CHO cell pools

[0148] 24 hours after transfection, cells were transferred to selection medium (medium without L-glutamine). 10mL selection medium was preheated in a T75 flask for each pool. Two stable pools were cultivated for each transfection. Cells were centrifuged (using 750x G for 7 minutes) and resuspended in 20mL selection medium, and incubated at 37°C with 8% CO2. During the selection process, cells were monitored by microscopy. Additional selection medium (5mL) was added after 7 days.

[0149] Passaging and production runs of stabilization pools

[0150] Once the cells reach at least 70% viability and 48 hours or shorter doubling time, the selection phase is considered successful. After selection, cells are passaged every two to three days, with 3x10E05 cells / mL in a 30mL total volume of culture medium (without L-glutamine) in a 125mL shake flask at 36.5°C and 5% CO2, starting with 120rpm shaking. Samples for titer measurement are regularly obtained. If the antibody titer is at least stable for 14 days, indicating phenotypic stability, a production run of at least 7 days is started.

[0151] For production runs, cells were inoculated at a density of 7x10E05 viable cells / mL in a shake flask in a total volume of 30 mL of basal medium without glutamine, and the cells were cultured at 34.5°C, 5% CO2, and 120 rpm shaking. During production runs of at least 7 days, cells were counted and samples for pH, glucose, and titer measurements were collected daily to adjust pH and glucose feed as needed. Starting from day 2, feed was supplemented daily (w / o glutamine). RAPIDlab was used. The pH was determined and the glucose level was measured via an EKF diagnostic device. During and / or at the end of the culture, the ForteBio with a protein A biosensor was used. The cell culture supernatant was analyzed for antibody titer after centrifugation using the production medium. Sample dilutions and standard curves were processed in the same production medium.

[0152] Example 1: Antibody expression in CHO cells using CHO wild-type glutamine synthetase as a metabolic selection marker Body Production

[0153] When the transgenic vector is stably integrated into the genome of the cells, CHO-K1-GS cells transfected with a vector carrying a selection marker for glutamine synthetase from Chinese hamster (CHO wild-type glutamine synthetase (GS), SEQ ID NO: 2) can survive selection when cultured in a medium not supplemented with L-glutamine.

[0154] CHO-K1-GS cells were transfected with a vector carrying the expression cassettes for monoclonal antibody 1 (mAb1) and CHO wild-type GS. After selection, the stable CHO pools were passaged as described above and samples were taken regularly for titer measurement of mAb1. Under the applied experimental conditions, the stable CHO pools (transfected with wild-type CHO GS) remained stable and highly productive for ~20 days post-transfection, with a decreasing level of productivity (titer) thereafter ( Figure 1 ).

[0155] Example 2: Use of Providencia larvae GS and other bacterial GS as selection markers in CHO cells Antibody production

[0156] For functional testing of novel bacterial glutamine synthetase variants, selection stringency (duration to achieve >70% viability after transfection), productive passages, and specific productivity were measured over time. For CHO pools that maintained productivity after extended passages, a subsequent 7-day production run in shake flasks was performed in a controlled process unit to additionally evaluate cell culture process parameters.

[0157] CHO-K1-GS cells were transfected with vectors carrying mAbl and an expression cassette for glutamine synthetase from either Chinese hamster hamster (SEQ ID NO:2) or Providencia larvae (SEQ ID NO:1), and viability, viable cell count (VCD), and productivity were measured over time during the selection phase. Surprisingly, CHO cells transfected with bacterial class I GS from Providencia larvae survived the selection process, suggesting that this prokaryotic metabolic selection marker is functional in CHO cells. Cells transfected with Providencia GS took longer to fully recover from selection compared to CHO GS ( Figure 2 A), and cells grow more slowly ( Figure 2 B), suggesting an increase in selection stringency.

[0158] Titers were measured during cell selection, indicating a rapid decrease in productivity of cells containing the CHO GS gene. Cells transfected with Providencia GS stably expressed mAb1 even after the selection process ( Figure 3 A). Production runs for at least an additional 7 days after selection and passaging indicated a significantly higher phenotypic stability of cells transfected with Providencia GS compared to CHO GS ( Figure 3 B) Cells transfected with CHO GS were not transferred into the production run due to productivity loss.

[0159] Overall, CHO cells transfected with Providencia larvae glutamine synthetase showed increased selection stringency and significantly higher productivity. In addition, the cell pool showed increased phenotypic stability and maintained productivity for at least 40 days, while cells transfected with CHO GS completely lost their productivity after ~20 days post-transfection.

[0160] In addition to the GS from Providencia larvae, a total of 10 prokaryotic GSs have been tested, 9 of which were derived from bacteria and 1 from an archaea (Methanocaldococcus janaschii). 6 were found to be functional in CHO cells, while 4 were not. Functional was defined as surviving the selection process and producing antibody producing cells. The results are summarized in Table B below, where (+++) indicates excellent performance that is superior to WT CHO GS, (++) indicates moderate performance that is similar to WT CHO GS, and (+) indicates moderate performance that is significantly inferior to WT CHO GS. At least most of the bacterial GSs that were successfully used for selection belong to the order Enterobacteriales and the family Morganellaceae and / or have at least 80% sequence identity with the GS from Providencia larvae. However, most of these bacterial GSs proved to show modest performance, clearly inferior to WT CHO GS when considering selection stringency and genetic stability, with the exception of GS from Photorhabditis luminescens that showed excellent performance (selection stringency / genetic stability) superior to WT CHO GS.

[0161] Table B

[0162]

[0163]

[0164] Selection stringency was analyzed by measuring >70% viability recovery, and genetic stability was confirmed by stable productivity over a certain period of time, e.g., more than 20 days after transfection. Representative dates for selection experiments using GS from Providencia larvae, Photorhabditis luminescens, and Budejovicia aquatica as selection markers to monitor viability of stable CHO pools are shown in Figure 4 A, and the productivity of CHO pools transfected with these bacterial GS is shown in Figure 3 D. Although GS from B. aquaticus was functional in CHO cells, the selection was not robust. In contrast, GS from Photorhabditis luminescens remained functionally active and showed even stronger attenuation activity compared to GS from Providencia larvae ( Figure 4A). Stable pools transfected with GS from Photorhabdus luminescens recovered (reached >70% viability) 16 to 17 days after transfection, compared to 13 days after transfection for GS from P. larvae. Productivity was comparable for GS from Photorhabdus luminescens and P. larvae, although slightly delayed for GS from Photorhabdus luminescens and strongly reduced for GS from B. aquaticus ( Figure 4 D).

[0165] These experiments demonstrated for the first time that bacterial GS, for example from Providencia larvae, can be used as a selection marker in mammalian cells, and further demonstrated that other bacterial GS, for example from Photorhabdus luminescens, that are closely related to bacterial GS from the Enterobacteriales and Morganellaceae and / or have at least 85% sequence identity to the amino acid sequence of GS from Providencia larvae (SEQ ID NO: 1) can be identified.

[0166] Example 3: Use of wild-type GS and E130F or E130G mutants of Providencia larvae as selection markers Antibody production in CHO cells

[0167] In addition, two different point mutations (E130F and E130G) of P. larvae GS were tested in selection and production experiments. CHO-K1-GS cells were transfected with vectors carrying expression cassettes for mAbl and wild-type glutamine synthetase from P. larvae (SEQ ID NO: 1) or glutamine synthetase from P. larvae containing mutations E130F (SEQ ID NO: 4) or E130G (SEQ ID NO: 5).

[0168] Both mutations appeared to further prolong the attenuation, resulting in a prolonged duration of cell detachment from selection compared to wild-type larval Providencia glutamine synthetase, and both demonstrated phenotypic stability. Subsequent production runs resulted in significantly improved overall titers ( Figure 5 ).

[0169] Example 4: Using wild-type GS and F226Y mutants of Providencia larvae as selection markers, Antibody production and VCD in CHO cells.

[0170] CHO-K1-GS cells were transfected with vectors carrying expression cassettes for mAbl and CHO wild-type GS (CHO WT GS), Providencia wild-type GS (SEQ ID NO: 1), or Providencia GS F226Y mutant (SEQ ID NO: 6). After stable pool generation and single cell sedimentation, the top clones were subjected to head-to-head shake flask experiments with CHO WT GS. Both Providencia wild-type GS and Providencia GS F226 outperformed CHO wild-type GS, showing titers (mg / L) that were approximately 50% higher than those of the CHO wild-type GS clones ( Figure 6 A). Cell clones with Providencia GS F226Y showed further increased growth behavior accompanied by higher viable cell density compared to Providencia wild-type GS ( Figure 6 B) This may offer advantages for biopharmaceutical production and especially for combination with the E130 mutation.

[0171] Example 5: Use of wild-type GS and R345A or R360A mutants of Providencia larvae as selection markers Antibody production and viability in CHO cells

[0172] In addition, two additional point mutants of the Providencia larvae glutamine synthetase were tested and evaluated in generating stable antibody producing CHO expression pools. Wild-type glutamine synthetase was tested head-to-head against variants with mutations in the catalytic domain of the selection marker.

[0173] While R360A lost functionality and the pool could not be recovered from the selection experiments, R345A remained functionally active but with strongly attenuated activity ( Figure 7 A). Stable pools transfected with R345A recovered (reached >70% viability) 31 days after transfection, in contrast to the wild-type protein which recovered in ~15 days. Interestingly, the strongly attenuated variant R345A (SEQ ID NO: 20) resulted in a 5-10 fold increase in productivity ( Figure 7 B).

[0174] Overall, the results from Examples 3, 4 and 5 demonstrate that, by introducing one or more point mutations at conserved residues involved in substrate binding, such as E130F, E130G, F226Y and / or R345A, bacterial GS, for example from Providencia larvae, can be further attenuated and thereby improved as a selection marker. Since these residues E130, F226 and R345 are also present in GS from Photorhabditis luminescens (amino acid sequence of SEQ ID NO: 14), it is expected that these mutations similarly further attenuate the identification of this bacterial GS and thereby improve this GS as a selection marker. In particular, the mutation F226Y showed a further increased growth behavior, accompanied by a higher viable cell density ( Figure 6 B) This may offer advantages for biopharmaceutical production and in particular for combination with the E130 mutation or the R345A mutation.

[0175] Sequence Listing

[0176]

[0177]

Claims

1. A mammalian expression vector comprising a polynucleotide encoding a bacterial glutamine synthetase as a selection marker, wherein the bacterial glutamine synthetase comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO:

1.

2. The mammalian expression vector of claim 1, wherein the bacterial glutamine synthetase is derived from a bacterium of the order Enterobacterales and the family Morganellaceae, preferably wherein the bacterial glutamine synthetase is derived from a Providencia species or a Photorhabdus species, more preferably wherein the bacterial glutamine synthetase is Providencia vermicola glutamine synthetase or Photorhabdus luminescens glutamine synthetase.

3. The mammalian expression vector of claim 1 or 2, wherein the bacterial glutamine synthetase comprises an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, and comprises a mutation selected from the group consisting of E130X, F226Y, R345A, and combinations thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, more preferably selected from the group consisting of Y, W, F, A, G, V, L, M, and I.

4. The mammalian expression vector of any one of claims 1 to 3, wherein the bacterial glutamine synthetase comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 14, and comprises a mutation selected from the group consisting of E130X, F226Y, R345A, and combinations thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, more preferably the aromatic or hydrophobic amino acid is selected from the group consisting of Y, W, F, A, G, V, L, M, and I.

5. The mammalian expression vector of any one of claims 1 to 4, wherein the mammalian expression vector further comprises at least one polynucleotide encoding a protein and / or non-coding RNA of interest, preferably comprises an expression cassette comprising at least one polynucleotide encoding a protein and / or non-coding RNA of interest.

6. The mammalian expression vector according to claim 5, wherein the protein of interest is a therapeutic protein, preferably selected from the group consisting of a cytokine, a hormone, a fusion protein, an antibody, an antibody-derived molecule and an antibody mimetic.

7. A nucleic acid sequence comprising a polynucleotide encoding a bacterial glutamine synthetase operably linked to a mammalian promoter, optionally further comprising at least one polynucleotide encoding a protein and / or non-coding RNA of interest, wherein the bacterial glutamine synthetase comprises an amino acid sequence having at least 85% sequence identity with the amino acid sequence of SEQ ID NO:

1.

8. The nucleic acid sequence of claim 7, wherein the bacterial glutamine synthetase comprises an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, and comprises a mutation selected from the group consisting of E130X, F226Y, R345A, and combinations thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, more preferably the aromatic or hydrophobic amino acid is selected from the group consisting of Y, W, F, A, G, V, L, M, and I.

9. A bacterial glutamine synthetase comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, and comprising a mutation selected from E130X, F226Y, R345A and combinations thereof, wherein X is any amino acid, preferably wherein the mutation in amino acid position E130 is a substitution with an aromatic or hydrophobic amino acid, more preferably the aromatic or hydrophobic amino acid is selected from Y, W, F, A, G, V, L, M and I.

10. A mammalian host cell comprising the expression vector of any one of claims 1 to 6, the nucleic acid sequence of claim 7 or 8, or a nucleic acid sequence encoding the bacterial glutamine synthetase of claim 9, preferably wherein the mammalian host cell is (a) a rodent cell, more preferably a CHO cell and / or (b) a GS gene knockout cell.

11. A method for preparing a cell that stably expresses a protein and / or non-coding RNA of interest, comprising (a) introducing an expression vector according to claims 1 to 6 or a nucleic acid according to claim 7 or 8 into a mammalian host cell, preferably a CHO cell, wherein the expression vector or nucleic acid comprises a polynucleotide encoding a bacterial glutamine synthetase and at least one polynucleotide encoding a protein and / or a non-coding RNA of interest; and (b) culturing the mammalian host cell in a medium lacking glutamine under conditions that select for bacterial glutamine synthetase, wherein the at least one polynucleotide encoding the protein and / or non-coding RNA of interest is co-integrated with the polynucleotide encoding the bacterial glutamine synthetase into the host cell genome.

12. The method of claim 11, further comprising (c) The step of isolating individual clones for clonal expansion to prepare monoclonal cell lines.

13. A method for producing a protein of interest, comprising (a) introducing a mammalian expression vector according to claims 1 to 6 or a nucleic acid according to claim 7 or 8 into a mammalian host cell, preferably a CHO cell, wherein the expression vector comprises a polynucleotide encoding a bacterial glutamine synthetase operably linked to a mammalian promoter and at least one polynucleotide encoding a protein of interest; (b) culturing the mammalian host cell in a medium lacking glutamine under conditions that select for bacterial glutamine synthetase, wherein the at least one polynucleotide encoding the protein of interest is co-integrated with the polynucleotide encoding the bacterial glutamine synthetase into the host cell genome; (c) optionally isolating individual clones for clonal expansion to produce monoclonal cell lines; (d) culturing the mammalian host cell under conditions whereby the protein of interest is produced; and (e) Harvesting and optionally purifying the protein of interest.

14. A method for producing a protein of interest, comprising (a) providing a mammalian host cell according to claim 10, comprising a polynucleotide encoding a bacterial glutamine synthetase and at least one polynucleotide encoding a protein of interest operably linked to a mammalian promoter; (b) culturing the mammalian host cell under conditions whereby the protein of interest is produced; and (c) Harvesting and optionally purifying the protein of interest.

15. The mammalian host cell of claim 10 or the method of any one of claims 11 to 14, wherein the mammalian host cell is a rodent cell, more preferably a CHO cell.

16. A kit comprising the expression vector according to any one of claims 1 to 6 and a cell culture medium that does not contain glutamine.

17. Use of bacterial glutamine synthetase as a selection marker in mammalian cells.

Citation Information

Patent Citations

  • Glutamine synthetase and its dedicated expression engineered bacteria and uses

    CN1884501A

  • Expression of wild type and mutant glutamine synthetase in foreign hosts

    EP0240792A1

  • Attenuated Glutamine Synthetase as a Selection Marker

    US20190352631A1

  • Process and materials for production of glucosamine and n-acetylglucosamine

    WO2004003175A2

  • Novel methods of diagnosis and treatment of m. tuberculosis infection and reagents therefor i

    WO2006000045A1